Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Change in Accured Expenses (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Change in Accured Expenses for 16 consecutive years, with -$75000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 932.13% to -$75000.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $278504.0, a 281.81% increase, with the full-year FY2025 number at $1.3 million, up 589.99% from a year prior.
  • Change in Accured Expenses was -$75000.0 for Q4 2025 at PharmaCyte Biotech, up from -$1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.4 million in Q2 2025 to a low of -$1.0 million in Q3 2025.
  • A 5-year average of $20300.2 and a median of $8192.5 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 2026.88% in 2022, then tumbled 1620.85% in 2025.
  • PharmaCyte Biotech's Change in Accured Expenses stood at -$501117.0 in 2021, then skyrocketed by 83.94% to -$80476.0 in 2022, then soared by 437.86% to $271896.0 in 2023, then crashed by 96.69% to $9013.0 in 2024, then tumbled by 932.13% to -$75000.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Change in Accured Expenses are -$75000.0 (Q4 2025), -$1.0 million (Q3 2025), and $1.4 million (Q2 2025).